MEDP: the cash flow

MyFinsight

For the year ending 2025-12-31, MEDP had -$172,387K decrease in cash & cash equivalents over the period. $681,867K in free cash flow.

Cash Flow	2025-12-31
Net income	451,123
Depreciation	27,178
Amortization	946
Stock-based compensation expense	34,786
Operating lease, right-of-use asset, periodic reduction	23,014
Income tax provision (benefit), deferred	80,773
Other	875
Accounts receivable and unbilled, net	106,215
Prepaid expenses and other current assets	27,101
Accounts payable	2,629
Accrued expenses	97,083
Advanced billings	143,805
Lease liabilities	-25,160
Other assets and liabilities, net	-11,237
Net cash provided by operating activities	713,223
Property and equipment expenditures	31,356
Other	-216
Net cash used in investing activities	-31,140
Proceeds from stock option exercises	57,001
Repurchases of common stock	917,389
Proceeds from revolving loan	0
Payments on revolving loan	0
Net cash used in financing activities	-860,388
Effect of exchange rates on cash, cash equivalents, and restricted cash	5,918
(decrease) increase in cash, cash equivalents, and restricted cash	-172,387
Cash and cash equivalents at beginning of period	669,436
Cash and cash equivalents at end of period	497,049

Unit: Thousand (K) dollars (except for numbers of shares and EPS).